Carvedilol Tablets Recalled for Carcinogenic N-Nitroso Impurity Manufacturing Defect
Glenmark Pharmaceuticals is recalling carvedilol tablets nationwide due to N-nitroso carvedilol I (NNCI-I), a carcinogenic impurity found in certain lots. The impurity exceeds FDA safety limits.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall with N-nitroso carvedilol I impurity, a known carcinogenic substance exceeding FDA safe limits, but with no reported illnesses or injuries. Classified as risk-of-harm where injury has not yet been reported per the severity rubric.
Plain-English summary
Glenmark Pharmaceuticals Inc., USA is recalling specific lots of Carvedilol tablets, USP, 12.5 mg distributed nationwide. The recall includes 500-tablet bottles (NDC 68462-164-05) and 100-tablet bottles (NDC 68462-164-01) with specific lot numbers and expiration dates listed in the FDA recall notice.
This recall stems from a manufacturing defect identified as a Current Good Manufacturing Practice (CGMP) deviation. Testing found N-Nitroso Carvedilol I (NNCI-I) impurity in affected lots at levels exceeding FDA-recommended limits.
Patients taking carvedilol should check the lot number and expiration date on their medication bottle. Patients should not stop their medication without first consulting their healthcare provider. Those with affected lots should contact their pharmacy or healthcare provider for replacement options.
More information about affected lot numbers and expiration dates is available on the FDA website and from Glenmark Pharmaceuticals.
The recalled product
- Product
- CARVEDILOL (CARVEDILOL)
- Brand
- CARVEDILOL
- Manufacturer
- Glenmark Pharmaceuticals Inc., USA
- Category
- Drug
- Hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Lot numbers: a) 17230658
- Exp.: 02/2025
- 17230814
- 17230822
- Exp.: 03/2025
- 17231004
- 17231009
- 17231022
- Exp.: 04/2025
- 17231393
- 17231392
- Exp.: 05/2025
- 17231538
- 17231541
- 17231542
- Exp.: 06/2025
- 17231710
- 17231718
- 17231721
- 17231722
UPCs (4)
- 0368462162019
- 0368462163016
- 0368462164013
- 0368462165010
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 2 recalled by Glenmark Pharmaceuticals Inc., USA under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same brand · CARVEDILOL
- HighMajor Pharmaceuticals carvedilol tablets recalled over nitrosamine impurity above FDA limit
FDA (Drugs) · 2025-08-27
- HighGlenmark carvedilol 25 mg tablets exceed the acceptable nitrosamine intake level
FDA (Drugs) · 2025-08-20
- HighCarvedilol 12.5 mg tablets recalled over nitrosamine above acceptable intake level
FDA (Drugs) · 2025-08-20
- HighCarvedilol 3.125 mg tablets recalled for nitrosamine impurity above intake limit
FDA (Drugs) · 2025-08-20
- HighCarvedilol 25 mg tablets recalled over nitrosamine impurity above FDA limit
FDA (Drugs) · 2025-08-20
Same manufacturer · Glenmark Pharmaceuticals Inc., USA
See all →- ModerateAzelaic Acid Gel 15% Recalled Over Grainy, Gritty, or Sandy Texture
FDA (Drugs) · 2026-08-05
- ModerateAlyacen 7/7/7 birth control tablets failed total impurities specification
FDA (Drugs) · 2026-06-24
- ModerateOndansetron tablets recalled because blister packs are not fully sealed
FDA (Drugs) · 2026-01-07
- CriticalFrozen chopped methi recalled after testing positive for Salmonella
FDA (Drugs) · 2025-12-17
- ModerateBisoprolol and hydrochlorothiazide tablets recalled over traces of another drug
FDA (Drugs) · 2025-12-10
Same hazard · n nitroso impurity
See all →- HighCinacalcet Tablets Recalled for N-Nitroso Impurity Exceeding Limits
FDA (Drugs) · 2026-07-08
- SevereCinacalcet Tablets Recalled for cGMP Deviations
FDA (Drugs) · 2026-07-08
- ModerateDuloxetine delayed-release capsules recalled for N-nitroso impurity contamination
FDA (Drugs) · 2026-05-13
- ModerateFurosemide tablets recalled for presence of N-nitroso impurity
FDA (Drugs) · 2026-04-29
- SevereFluoxetine Tablets 20 mg Recalled for N-Nitroso Impurity
FDA (Drugs) · 2025-06-11